Brief: Cantargia Presents Early Results With Nadunolimab In MDS And AML
04/11/2026 14:01
BRIEF-Cantargia Presents Early Results With Nadunolimab In MDS And AML Nov 4 (Reuters) - Cantargia AB CANTA.ST:
CANTARGIA PRESENTS PROMISING EARLY RESULTS WITH NADUNOLIMAB IN MDS AND AML AHEAD OF ASH 2026
TRIAL SHOWS 70% RESPONSE IN MDS, 33% RESPONSE IN AML WITH NADUNOLIMAB COMBINATIONS
Source text: ID:nMFN8vzpVJ
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))